BRUERA, GEMMA
BRUERA, GEMMA
Dipartimento di Scienze cliniche applicate e biotecnologiche
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases
2022-01-01 Guadagni, Stefano; Masedu, Francesco; Fiorentini, Giammaria; Sarti, Donatella; Fiorentini, Caterina; Guadagni, Veronica; Apostolou, Panagiotis; Papasotiriou, Ioannis; Parsonidis, Panagiotis; Valenti, Marco; Ricevuto, Enrico; Bruera, Gemma; Farina, Antonietta R; Mackay, Andrew R; Clementi, Marco
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice
2021-01-01 Bruera, Gemma; Pepe, Francesco; Malapelle, Umberto; Di Staso, Mario; Dal Mas, Antonella; Di Giacomo, Daniela; Scerbo, Gaia; Santilli, Michela; Ciacco, Eugenio; Simmaco, Maurizio; Troncone, Giancarlo; Coco, Claudio; Giuliante, Felice; Ricevuto, Enrico
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments
2020-01-01 Bruera, Gemma; Ricevuto, Enrico
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study
2020-01-01 Guadagni, S.; Clementi, M.; Mackay, A. R.; Ricevuto, E.; Fiorentini, G.; Sarti, D.; Palumbo, P.; Apostolou, P.; Papasotiriou, I.; Masedu, F.; Valenti, M.; Giordano, A. V.; Bruera, G.
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease
2020-01-01 Bruera, Gemma; Ricevuto, Enrico
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithKRASMutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy
2020-01-01 Bruera, G; D'Andrilli, A; Simmaco, M; Guadagni, S; Rendina, Ea; Ricevuto, E
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A
2020-01-01 Guadagni, Stefano; Farina, Antonietta; Cappabianca, LUCIA ANNA MARIA; Sebastiano, Michela; Maccarone, Rita; Zelli, Veronica; Clementi, Marco; Chiominto, Alessandro; Bruera, Gemma; Ricevuto, Enrico; Fiorentini, Giammaria; Sarti, Donatella; Mackay, ANDREW REAY
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study
2019-01-01 Guadagni, S.; Fiorentini, G.; Mambrini, A.; Masedu, F.; Valenti, M.; Mackay, A. R.; Sarti, D.; Ricevuto, E.; Clementi, M.; Catarci, M.; Lazzarin, Gianni; Bruera, G.
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers.
2019-01-01 Bruera, Gemma; Massacese, Silvia; Pepe, Francesco; Malapelle, Umberto; Dal Mas, Antonella; Ciacco, Eugenio; Calvisi, Giuseppe; Troncone, Giancarlo; Simmaco, Maurizio; Ricevuto, Enrico
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: An experience of multidisciplinary management in clinical practice
2019-01-01 Bruera, G.; Giuliani, A.; Romano, L.; Chiominto, A.; Di Sibio, A.; Mastropietro, S.; Cosenza, P.; Ricevuto, E.; Schietroma, M.; Carlei, F.
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy.
2018-01-01 Bruera, Gemma; Francesco, Pepe; Umberto, Malapelle; Pasquale, Pisapia; Antonella Dal Mas, ; DI GIACOMO, Daniela; Calvisi, Giuseppe; Giancarlo, Troncone; Ricevuto, Enrico
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study
2018-01-01 Bruera, G.; Massacese, S.; Candria, S.; Galvano, A.; Manetta, R.; Giordano, A. V.; Carducci, S.; Di Sibio, A.; Ciacco, E.; Russo, A.; Ricevuto, E.
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease.
2018-01-01 Tessitore, A; Bruera, G; Mastroiaco, V; Cannita, K; Cortellini, A; Cocciolone, V; Dal Mas, A; Calvisi, G; Zazzeroni, F; Ficorella, C; Ricevuto, E; Alesse, E
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer
2018-01-01 Bruera, Gemma; Di Staso, Mario; Bonfili, Pierluigi; Galvano, Antonio; Manetta, Rosa; Coletti, Gino; Vicentini, Roberto; Guadagni, Stefano; Ficorella, Corrado; DI CESARE, Ernesto; Ricevuto, Enrico
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy
2017-01-01 Bruera, Gemma; Russo, Antonio; Galvano, Antonio; Rizzo, Sergio; Ricevuto, Enrico
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease
2016-01-01 Tessitore, Alessandra; Bruera, Gemma; Mastroiaco, Valentina; Cannita, K; Cortellini, Alessio; dal mas, A; Zazzeroni, Francesca; Ficorella, Corrado; Ricevuto, Enrico; Alesse, Edoardo
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
2015-01-01 Bruera, Gemma; Cannita, K; Tessitore, Alessandra; Russo, A; Alesse, Edoardo; Ficorella, Corrado; Ricevuto, Enrico
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study
2015-01-01 Ricevuto, Enrico; Cocciolone, Valentina; Mancini, MARIA VINCENZA; Cannita, Katia; Romano, Silvio; Bruera, Gemma; Pelliccione, Michela; Adinolfi, Maria Ilaria; Ciccozzi, Antonietta; Bafile, Alberto; Penco, Maria; Ficorella, Corrado
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx).
2013-01-01 Bruera, Gemma; Cannita, K; Di Giacomo, D; Lamy, A; Frebourg, T; Sabourin, Jc; Tosi, M; Alesse, Edoardo; Ficorella, Corrado; Ricevuto, Enrico
Effectiveness and safety of intensive triplet chemotherapy plus bevecizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer
2013-01-01 Bruera, Gemma; Cannita, K; Giordano, Av; Vicentini, R; Ficorella, Corrado; Ricevuto, Enrico